Two developments reshaped the sequencing and proteomics landscape: the Federal Circuit remanded Guardant Health’s patent dispute with TwinStrand to the Patent Trial and Appeal Board for further validity review, and San Diego protein‑sequencing firm Encodia ceased operations and moved to auction lab equipment after an assignment for the benefit of creditors. The Guardant remand may improve Guardant’s prospects in a case that previously produced an $83.4 million damages award; the Encodia closure removes a proteomics startup from the market and raises questions about commercialization paths for novel protein‑sequencing technologies. Together, they underscore both legal risk and capital fragility in next‑generation sequencing ventures.